Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t ...

Discover how the dry air of winter affects your nose and how to combat the drying out with helpful tips and treatments.

MUNICH, Germany I January 30, 2025 I Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced ...

The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...

The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.

A graduate of Stanford University’s prestigious EENT Innovation Biodesign program in 2019, Diag-Nose.io is redefining ...

A groundbreaking approach led by a team of scientists, including Rice University chemist James Tour, has the potential to ...

Intranasal foralumab can modulate a number of immune cell types in people with non-active SPMS, developer Tiziana Life ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.